PERRIGO Co plc
For the period ended Jun 28, 2025. Filed Aug 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 28, 2025 · Filed Aug 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Goodwill and Intangible Assets
NOTE 8 -GOODWILL AND INTANGIBLE ASSETS
Goodwill
Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
| December 31, 2024 | Impairments | Currency translation adjustments | June 28, 2025 | |
|---|---|---|---|---|
| CSCA(1) | $2,076.1 | $— | $9.6 | $2,085.7 |
| CSCI(2) | 1,244.1 | (1.2) | 150.6 | 1,393.5 |
| Total goodwill | $3,320.2 | $(1.2) | $160.2 | $3,479.2 |
(1) We had accumulated goodwill impairments of $6.1 million as of June 28, 2025 and December 31, 2024.
(2) We had accumulated goodwill impairments of $997.1 million and $995.9 million as of June 28, 2025 and December 31, 2024, respectively.
Richard Bittner Business Goodwill
On March 10, 2025, the Company signed a definitive agreement to sell the Richard Bittner Business to HBI Health & Beauty Innovations Limited. As a result, we determined an impairment indicator existed and prepared a quantitative goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment charge of $1.2 million within our CSCI segment during the three months ended March 29, 2025. On April 11, 2025, we completed the sale of the Richard Bittner Business to HBI Health & Beauty Innovations Limited (refer to Note 3 and Note 9).
Note 8
Intangible Assets
Intangible assets and related accumulated amortization consisted of the following(1) (in millions):
| June 28, 2025 | December 31, 2024 | |||
|---|---|---|---|---|
| Gross | AccumulatedAmortization | Gross | AccumulatedAmortization | |
| Indefinite-lived intangibles: | ||||
| Trademarks, trade names, and brands | $3.6 | $— | $3.3 | $— |
| In-process research and development | 1.9 | — | 1.9 | — |
| Total indefinite-lived intangibles | $5.5 | $— | $5.2 | $— |
| Definite-lived intangibles: | ||||
| Distribution and license agreements and supply agreements | $106.8 | $64.8 | $101.9 | $59.5 |
| Developed product technology, formulations, and product rights | 351.7 | 239.1 | 341.5 | 227.2 |
| Customer relationships and distribution networks | 1,901.3 | 1,255.3 | 1,750.6 | 1,112.3 |
| Trademarks, trade names, and brands | 2,570.6 | 813.2 | 2,301.5 | 672.8 |
| Non-compete agreements | 2.1 | 2.1 | 2.1 | 2.1 |
| Total definite-lived intangibles | $4,932.5 | $2,374.5 | $4,497.6 | $2,073.9 |
| Total intangible assets | $4,938.0 | $2,374.5 | $4,502.8 | $2,073.9 |
(1) Certain intangible assets are denominated in currencies other than U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements.
During the three months ended June 28, 2025, we identified an impairment indicator related to our Prevacid® definite-lived intangible asset in our CSCA segment. The indicator related to expected long-term decline in contribution margin. We determined a fair value assessment of the asset was required. The assessment resulted in an asset impairment of $1.5 million (refer to Note 9).
We recorded amortization expense of $56.6 million and $111.4 million for the three and six months ended June 28, 2025, respectively, and $57.5 million and $115.9 million for the three and six months ended June 29, 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.